An average trading volume for MacroGenics Inc. (MGNX) has been steady over the recent period.

After finishing at $5.88 in the prior trading day, MacroGenics Inc. (NASDAQ: MGNX) closed at $6.45, up 9.69%. In other words, the price has increased by $+0.57 from its previous closing price. On the day, 762444 shares were traded. MGNX stock price reached its highest trading level at $6.47 during the session, while it also had its lowest trading level at $5.87.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



Our goal is to gain a better understanding of MGNX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.90 and its Current Ratio is at 3.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

On November 14, 2022, BMO Capital Markets Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $5.70 to $16.

SMBC Nikko Downgraded its Outperform to Neutral on July 18, 2022, while the target price for the stock was maintained at $5.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 10 when Peters Jeffrey Stuart sold 5,372 shares for $6.03 per share. The transaction valued at 32,393 led to the insider holds 0 shares of the business.

BIOTECH TARGET N V bought 500,000 shares of MGNX for $2,532,600 on Feb 14. The 10% Owner now owns 9,579,963 shares after completing the transaction at $5.07 per share. On Jan 19, another insider, BIOTECH TARGET N V, who serves as the 10% Owner of the company, bought 150,000 shares for $5.30 each. As a result, the insider paid 794,925 and bolstered with 9,079,963 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 4.94 while its Price-to-Book (P/B) ratio in mrq is 3.22.

Stock Price History:

Over the past 52 weeks, MGNX has reached a high of $10.20, while it has fallen to a 52-week low of $2.13. The 50-Day Moving Average of the stock is 5.82, while the 200-Day Moving Average is calculated to be 4.74.

Shares Statistics:

The stock has traded on average 660.47K shares per day over the past 3-months and 672.33k shares per day over the last 10 days, according to various share statistics. A total of 61.46M shares are outstanding, with a floating share count of 59.88M. Insiders hold about 0.10% of the company’s shares, while institutions hold 94.50% stake in the company. Shares short for MGNX as of Jan 30, 2023 were 4.6M with a Short Ratio of 4.43M, compared to 4.15M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 7.48% and a Short% of Float of 9.88%.

Earnings Estimates

Its stock is currently analyzed by 11 different market analysts. On average, analysts expect EPS of $0.25 for the current quarter, with a high estimate of $1.26 and a low estimate of -$0.79, while EPS last year was -$0.95. The consensus estimate for the next quarter is -$0.38, with high estimates of $0.19 and low estimates of -$0.84.

Analysts are recommending an EPS of between -$0.86 and -$2.95 for the fiscal current year, implying an average EPS of -$1.88. EPS for the following year is -$2.34, with 11 analysts recommending between -$1.27 and -$3.18.

Revenue Estimates

9 analysts predict $70.12M in revenue for the current quarter. It ranges from a high estimate of $135.44M to a low estimate of $13.7M. As of the current estimate, MacroGenics Inc.’s year-ago sales were $14.15M, an estimated increase of 395.70% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $38.45M, an increase of 246.40% less than the figure of $395.70% in the same quarter last year. There is a high estimate of $64.86M for the next quarter, whereas the lowest estimate is $15.77M.

A total of 11 analysts have provided revenue estimates for MGNX’s current fiscal year. The highest revenue estimate was $214.28M, while the lowest revenue estimate was $92.6M, resulting in an average revenue estimate of $154.16M. In the same quarter a year ago, actual revenue was $77.45M, up 99.10% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $88.2M in the next fiscal year. The high estimate is $124.69M and the low estimate is $17M. The average revenue growth estimate for next year is down -42.80% from the average revenue estimate for this year.